We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dospělá výška dětí, které se narodily malé na svůj gestační věk (SGA), s malou výškou v dětství (SGA-SS). Výsledky léčby růstovým hormonem z dat české národní databáze REPAR
- Authors
Ledjona, Toni; Lukáš, Plachý; Barbora, Jírová; Irena, Hainerová Aldhoon; Darina, Aleksijevi; Jana, Černá; Marcela, Dvořáková; Eva, El-Lababidi; Božena, Kalvachová; Kamila, Kocourková; Ivana, Kotvalová; Olga, Magnová; Dana, Novotná; Barbora, Obermannová; Renata, Pomahačová; Štěpánka, Průhová; Ondřej, Souček; Jiří, Strnadel; Lucie, Šíchová; Jaroslav, Škvor
- Abstract
Of children born small for gestational age (SGA) with birth weight and/or birth length below −2 SD, about 10% fail to catch-up after birth. These children remain short over childhood (with height standard deviation score [ht-SDS] below −2.5 SDS) and end up as short adults. They are assigned as SGA-SS (small for gestational age with short stature). European Medicine Agency approved growth hormone therapy in SGA-SS already in 2003. Out of 1502 SGA-SS children that are registered in the Czech national database of growth hormone recipients REPAR, 397 children (221 boys) already completed growth and achieved near-final height. Growth hormone therapy (median dose 0.034 mg/kg/day) was initiated at age 8.5 years in boys (median; P5-95: 3.2-15.0) and 7.3 years in girls (3.9-13.5). The mean ht-SDS at treatment initiation was −3.21 (SD: 0.91). Treatment was terminated at age 16.2 years in boys (median; P5-95: 14.0-18.7) and 14.3 years in girls (12.4-17.3). By treatment termination, the patients have had gained 1.59 ht-SDS (mean) and have achieved near-final height −1.62 ht-SDS (SD: 0.97; p<0.0001 if compared to pre-treatment). Thus, majority of patients exceeded −2 SDS at treatment completion and achieved height within normal limits. After adjusting for ht-SDS at age 18 years, their height corresponded to ht-SDS −2.30 (SD: 1.09; p < 0.0001 if compared to pre-treatment). Growth hormone therapy was successful even after this adjustment that mildly underestimates the treatment effect, and led to mean height increase of 0.91 ht-SDS. Analysis results of the REPAR database confirm efficacy of growth hormone therapy in SGA-SS children and its potential to significantly improve the adult height.
- Subjects
SMALL for gestational age; TERMINATION of treatment; HORMONE therapy; SOMATOTROPIN; SHORT stature
- Publication
Czecho-Slovak Pediatrics / Česko-Slovenská Pediatrie, 2023, Vol 78, p22
- ISSN
0069-2328
- Publication type
Article